Navigation Links
Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29

Company to Proceed with Development Program for Oral Compounds to Treat Alcohol Dependence

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc. (Nasdaq: ALKS) today announced positive preliminary results from a clinical trial of ALKS 29 in alcohol dependent patients. Based on these results, the company plans to move forward with its development program for oral product candidates to treat alcohol dependence. ALKS 29 is a combination of two agents with distinct pharmacologic properties designed to provide advantages over current oral medications for the treatment of alcohol dependence. In the study, ALKS 29 was generally well tolerated and led to both a statistically significant increase in the percent of days abstinent and a decrease in drinking compared to placebo when combined with psychosocial therapy.

"We are encouraged by the positive results from this initial proof of concept study, which provide further rationale for the continued expansion of our addiction franchise," stated Elliot Ehrich, chief medical officer of Alkermes. "Addiction is an underserved disease area where a variety of treatments are needed that can improve outcomes for patients. We look forward to the complete analysis of these data, as we believe insights from this study could help pave the way for the development of ALKS 29 and other proprietary oral compounds for the treatment of alcohol dependence."

In the phase 1/2 study, patients treated with ALKS 29 demonstrated statistically significant improvement compared to placebo in terms of percent of days abstinent, percent of heavy drinking days, and average number of drinks per day. ALKS 29 was generally well tolerated during the study.

The phase 1/2 multi-center, randomized, double-blind, placebo-controlled, eight-week study was designed to assess the efficacy and safety of ALKS 29 in approximately 150 alcohol dependent patients. The study e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/2/2015)...   Physicians Rx Pharmacy ("PRxP") today announced ... organization as President and Chief Executive Officer.  ... Chief Executive Officer for Soleo Health Specialty Infusion Services, ... Rx Pharmacy, be responsible for leading the rapidly-growing 340B ... to bring Gaston on as the President and CEO ...
(Date:9/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ... Latin America (London, UK - November 16-18, 2015)" conference to their ... Latin America including Columbia, Peru , ... , Uruguay , Paraguay , ... Central America , Chile This ...
(Date:9/2/2015)... , Sept. 2, 2015 Research ... addition of the "Medical Device Studies: Clinical ... conference to their offering. This ... are involved in gathering clinical evidence required for ... is required for all medical devices and the ...
Breaking Medicine Technology:Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... March 15, 2011 AstraZeneca today announced enrolment of ... for NKTR-118, an oral peripherally-acting opioid antagonist being investigated ... III clinical programme is designed to investigate the safety ... opioid induced constipation, a common side effect of prescription ...
... March 15, 2011 Southern Home Medical Equipment, ... services, healthcare professionals and equipment to medical institutions, ... growth.  After two consecutive profitable years, zero long-term ... to pursue additional revenues and growth opportunities. ...
Cached Medicine Technology:AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation 2AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation 3Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area 2
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Date and ... at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa 19009 , ... host a day-long seminar featuring New York Times best-selling author Sam Keen based on ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Affairs Officer following the departure of Kristen Dietz, former Chief Operations Officer. ... released the following statement welcoming Mr. Salot: “ Stanley H. Salot Jr , ...
(Date:9/2/2015)... ... September 02, 2015 , ... The medical waste management market is expected to ... CAGR of 5.2%. The global medical waste management market is segmented based on type ... is expected to register the highest growth rate in the medical waste management market, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda ... in commemorating “Hunger Action Month” during the entire month of September. In ... will be dedicating its efforts this September to an awareness campaign educating legislators ...
(Date:9/2/2015)... Omaha, Neb. (PRWEB) , ... ... ... one of the nation’s largest and fastest-growing interim clinical staffing companies, has ... (BPOC) and Heritage Group.         , BPOC and Heritage Group each ...
Breaking Medicine News(10 mins):Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Healtec® Announces Executive Leadership Change 2Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 2Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 3Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 4Health News:Medical Waste Management Market Growing at 5.2% CAGR to 2020 5Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4
... 5 in the February 2008 edition (Volume 6, Issue ... team found that the hypertension drugs diltiazem and verapamil ... with the conditions Gaucher disease, -mannosidosis, and type IIIA ... reprogramming the innate protein homeostasis machinery of the cell ...
... WASHINGTON, Feb. 4 "Congress must reject,President Bush,s Fiscal ... needs of the over 1.1 million people living with ... Director of The AIDS,Institute. "Most of the people who ... are very poor and from minority communities.,As the richest ...
... largest of its kind , , MONDAY, Feb. 4 (HealthDay News) ... link between the measles, mumps and rubella (MMR) vaccine and ... theirs was the third and largest study that has looked ... has failed to find one. , "I think it,s fabulous ...
... Gilbert Hospital is,celebrating its second anniversary. Gilbert,s first ... more than 93,000 patients and has a,staff exceeding 350. ... room wait times of less than 31 minutes, Gilbert,Hospital ... this pledge,more than 98.5 percent of the time. "There ...
... Feb. 4 - President George W.,Bush today submitted ... 2009.,In response Bruce Roberts, RPh, executive vice president ... issued the following,statement:, "President Bush,s efforts to ... health care, and even more specifically the Medicare,and ...
... a consulting firm,dedicated exclusively to improving the pharmacy ... the recent,introduction of the ARMSRx E-Audit, their upgraded ... often overlooked piece of the prescription,benefits package. The ... of opportunities in which errors can occur. Fraud, ...
Cached Medicine News:Health News:Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells 2Health News:Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells 3Health News:Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells 4Health News:President's FY09 Budget - A Disaster for Domestic AIDS: Congress Must Fund Critical Healthcare Priorities 2Health News:President's FY09 Budget - A Disaster for Domestic AIDS: Congress Must Fund Critical Healthcare Priorities 3Health News:Another Study Finds No Link Between MMR Vaccine and Autism 2Health News:Another Study Finds No Link Between MMR Vaccine and Autism 3Health News:Gilbert Hospital Turns Two 2Health News:NCPA Statement in Response to President Bush's FY 2009 Budget Proposal 2Health News:ARMSRx Tackles the New Rx Addiction -- Pharmacy Benefit Audits 2
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... The NOW Hepatitis B test is a ... diagnosis of a Hepatitis B infection. This simple, ... for accurate treatment and improved patient outcomes. , ... is an in vitro immunodiagnostic test for the ...
... is the newest technology available in acrylic ... combines exceptional material and design properties to ... Biostability , Unique foldable hydrophobic acrylic material ... be biostable , High index of ...
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
Medicine Products: